Escitalopram and Depression in Elderly Alzheimer's Patients
Information source: University of British Columbia
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Depressive Disorder
Intervention: Escitalopram (Drug)
Phase: Phase 3
Status: Not yet recruiting
Sponsored by: University of British Columbia Official(s) and/or principal investigator(s):
Kiran Rabheru, MD, Principal Investigator, Affiliation: University of British Columbia
Overall contact:
Mario McKenna, Phone: 604-875-4111, Ext: 62410, Email: mario.mckenna@vch.ca
Summary
To investigate the effect of Escitalopram in a large and diverse of dementia patients
suffering from depression.
Clinical Details
Official title: An Open-Label Study of Escitalopram in the Treatment of Major Depressive Disorder in Elderly Patients With Alzheimer's Disease
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Primary outcome: Change in Cornell Scale for Depression in Dementia (CSDD) from baseline.
Secondary outcome: Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study
Detailed description:
This study will assess the efficacy, tolerability, and safety of escitalopram in the
treatment of Major Depressive Disorder in patients with Alzheimer's disease over a 24-week
period. It will also assess the efficacy and tolerability of escitalopram after 12 weeks of
treatment.
Eligibility
Minimum age: 50 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- > 50 years
- Male & female
- Alzheimer's disease
- Depressive episode
Locations and Contacts
Mario McKenna, Phone: 604-875-4111, Ext: 62410, Email: mario.mckenna@vch.ca
Vancouver General Hospital, Vancouver, British Columbia, Canada
Mt. St. Joseph's Hospital, Vancouver, British Columbia, Canada
Additional Information
Starting date: September 2008
Ending date: December 2009
Last updated: September 24, 2008
|
